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Low-level resistance to fluoroquinolones among Salmonella and
Shigella
We have read with interest the recent article by Willke et al.
[1] on resistance of Salmonella and Shigella in Turkey. As pub-
lished by Willke ‘‘there are alarming reports of reduced sus-
ceptibility and even resistance of Salmonella strains to
quinolones’’. Clinicians and microbiologists have to keep in
mind this risk since failures of treatment of typhoid fever with
ciprofloxacin have been reported [2,3,4] and particularly with
strains that have low-level resistance to fluoroquinolones [5,6].
This paper described Salmonella strains with reduced sus-
ceptibility to fluoroquinolones: for example, the MICs of Sal-
monella typhi to pefloxacin, ofloxacin and ciprofloxacin were 4,
1 and 0.5 mg/L, respectively. It is probably due to a percentage
of strains with low-level resistance especially in Salmonella typhi.
We are thus interested to know how many strains had low-
level resistance to fluoroquinolones in this study? The author
should provide the distribution of the minimum inhibitory
concentrations and the percentage that were nalidixic acid-
resistant.
We strongly suggest that nalidixic acid is tested against all
Salmonella isolates to detect this low level of resistance and
against isolates from acute shigellosis where nalidixic acid can
be used for treatment of children. It is known in Gram-negative
bacilli that fluoroquinolone resistance is most frequently a two-
stage process, with resistance to older quinolones such as nal-
idixic acid emerging first, conferring higher MICs for the
fluoroquinolones, but usually staying within the ‘‘susceptible’’
range. This is followed by further mutations to generate high-
level resistance to the fluoroquinolones.
In conclusion, the number of strains with low-level resist-
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ance to fluoroquinolones is certainly underestimated, since, in
the usual susceptibility tests, with the breakpoints presently
accepted world-wide, such strains are categorized as susceptible.
Strains resistant to nalidixic acid should be reported to the
clinician and the MIC of ciprofloxacin measured.
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